← back to search

Jieming Qu

Shanghai Jiao Tong University · CN
Area of research
Infectious Diseases · Molecular Medicine
Research interest
Research interests include COVID-19 Clinical Research Studies, SARS-CoV-2 and COVID-19 Research, Antibiotic Resistance in Bacteria, and Long-Term Effects of COVID-19.
h-index
41
citations
10,107
works
195
NIH funding
primary concept
email

Recent publications

Baseline characteristics of patients in the Chinese Bronchiectasis Registry (BE-China): a multicentre prospective cohort study
The Lancet Respiratory Medicine 2025cited by 25position: middledoi
Guidelines for the diagnosis, treatment, prevention and control of infections caused by carbapenem-resistant gram-negative bacilli
Journal of Microbiology Immunology and Infection 2023cited by 128position: middledoi
Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study
The Lancet Regional Health - Western Pacific 2023cited by 111position: middledoi
Mobilizable plasmids drive the spread of antimicrobial resistance genes and virulence genes in Klebsiella pneumoniae
Genome Medicine 2023cited by 53position: lastdoi
Nebulized exosomes derived from allogenic adipose tissue mesenchymal stromal cells in patients with severe COVID-19: a pilot study
Stem Cell Research & Therapy 2022cited by 183position: lastdoi
Inhibition of myeloid-derived suppressor cell arginase-1 production enhances T-cell-based immunotherapy against Cryptococcus neoformans infection
Nature Communications 2022cited by 49position: middledoi
Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline
European Respiratory Journal 2022cited by 45position: middledoi
The Establishment of China Bronchiectasis Registry and Research Collaboration (BE-China): Protocol of a prospective multicenter observational study
Respiratory Research 2022cited by 12position: middledoi
Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline
European Respiratory Journal 2021cited by 229position: middledoi
Preclinical efficacy and clinical safety of clinical‐grade nebulized allogenic adipose mesenchymal stromal cells‐derived extracellular vesicles
Journal of Extracellular Vesicles 2021cited by 212position: lastdoi
Nebulized Colistin in Ventilator-Associated Pneumonia and Tracheobronchitis: Historical Background, Pharmacokinetics and Perspectives
Microorganisms 2021cited by 57position: middledoi
Effectiveness of convalescent plasma therapy in severe COVID-19 patients
Proceedings of the National Academy of Sciences 2020cited by 2,028position: middledoi
Coronavirus disease 2019 (COVID-19): a clinical update
Frontiers of Medicine 2020cited by 486position: lastdoi
Evidence-based Guideline for Therapeutic Drug Monitoring of Vancomycin: 2020 Update by the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society
Clinical Infectious Diseases 2020cited by 164position: middledoi
Clinical outcomes of COVID-19 in Wuhan, China: a large cohort study
Annals of Intensive Care 2020cited by 145position: middledoi
Assessing risk factors for SARS-CoV-2 infection in patients presenting with symptoms in Shanghai, China: a multicentre, observational cohort study
The Lancet Digital Health 2020cited by 55position: middledoi
RETRACTED ARTICLE: Effect of hCMSCs and liraglutide combination in ALI through cAMP/PKAc/β-catenin signaling pathway
Stem Cell Research & Therapy 2020cited by 42position: middledoi
Evaluating the diagnostic accuracy of a ctDNA methylation classifier for incidental lung nodules: protocol for a prospective, observational, and multicenter clinical trial of 10,560 cases
Translational Lung Cancer Research 2020cited by 13position: middledoi
VTE Risk Profiles and Prophylaxis in Medical and Surgical Inpatients
CHEST Journal 2018cited by 96position: middledoi
Diagnosis and treatment of community‐acquired pneumonia in adults: 2016 clinical practice guidelines by the Chinese Thoracic Society, Chinese Medical Association
The Clinical Respiratory Journal 2017cited by 318position: lastdoi
Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects
International Journal of Cancer 2017cited by 233position: lastdoi
Mesenchymal Stem Cell Microvesicles Attenuate Acute Lung Injury in Mice Partly Mediated by <i>Ang-1</i> mRNA
Stem Cells 2017cited by 222position: lastdoi
Fibroblast Growth Factor-10 (FGF-10) Mobilizes Lung-resident Mesenchymal Stem Cells and Protects Against Acute Lung Injury
Scientific Reports 2016cited by 70position: middledoi
Intravenous combined with aerosolised polymyxin versus intravenous polymyxin alone in the treatment of pneumonia caused by multidrug-resistant pathogens: a systematic review and meta-analysis
International Journal of Antimicrobial Agents 2015cited by 68position: lastdoi
Human Mesenchymal Stem Cell Microvesicles for Treatment of <i>Escherichia coli</i> Endotoxin-Induced Acute Lung Injury in Mice
Stem Cells 2013cited by 703position: middledoi
The changes induced by cyclophosphamide in intestinal barrier and microflora in mice
European Journal of Pharmacology 2013cited by 149position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Yinggang Zhu · Shanghai Medical College of Fudan University7 papers (2013–2022)Antoine Monsel · Inserm5 papers (2013–2022)Bin Cao · Xi'an University of Science and Technology3 papers (2017–2022)Κατερίνα Αντωνίου · KU Leuven2 papers (2021–2022) · 2 papers (2021–2022)Marc Humbert · Médecins Sans Frontières2 papers (2021–2022)Stefano Aliberti · University of Haifa2 papers (2021–2022)Chen Wang · Stanford University2 papers (2021–2022)Haixia Liu · Fudan University2 papers (2015–2017)Yuanlin Song · Shanghai Medical College of Fudan University2 papers (2016–2020)Megan Crichton · University of Dundee2 papers (2021–2022)Mengmeng Shi · Dalian Medical University2 papers (2021–2022) · 2 papers (2021–2022)Nicolás Roche · Hospital Universitario Fundación Jiménez Díaz2 papers (2021–2022)Daiana Stolz · Friedrich Schiller University Jena2 papers (2021–2022)Thomy Tonia · Institute of Social and Preventive Medicine2 papers (2021–2022)Thomas Vandendriessche · KU Leuven2 papers (2021–2022)Michal Shteinberg · Technion – Israel Institute of Technology2 papers (2021–2022)Jin‐Fu Xu · Tongji University2 papers (2017–2022)Christopher E. Brightling · University of Leicester2 papers (2021–2022)